PDCD1 and head and neck squamous cell carcinoma: ,20 However, another single-arm phase 1b clinical trial has reported that the combination of anti-PD-1 (toripalimab) and chemotherapy (gemcitabine and cisplatin) achieved an MPR rate of only 44.5% in 18 patients with locally advanced HNSCC (30.3% OPSCC and 69.7% OSCC).21